WealthCare Asset Management LLC Sells 1,268 Shares of Amgen Inc. $AMGN

WealthCare Asset Management LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 35.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,292 shares of the medical research company’s stock after selling 1,268 shares during the quarter. Amgen comprises about 0.8% of WealthCare Asset Management LLC’s investment portfolio, making the stock its 26th biggest position. WealthCare Asset Management LLC’s holdings in Amgen were worth $966,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Rational Advisors Inc. increased its position in shares of Amgen by 13.7% during the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock valued at $72,000 after purchasing an additional 24 shares during the last quarter. Beacon Financial Advisory LLC lifted its position in Amgen by 2.0% in the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock worth $461,000 after buying an additional 25 shares during the last quarter. James T. Borello RIA lifted its position in Amgen by 13.6% in the third quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock worth $88,000 after buying an additional 25 shares during the last quarter. Sweeney & Michel LLC lifted its position in Amgen by 0.5% in the third quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock worth $2,162,000 after buying an additional 25 shares during the last quarter. Finally, Legacy Financial Advisors Inc. boosted its stake in Amgen by 0.8% during the second quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock worth $1,234,000 after buying an additional 26 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of AMGN opened at $444.63 on Tuesday. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The stock has a market capitalization of $240.38 billion, a PE ratio of 27.63, a PEG ratio of 3.21 and a beta of 0.41. The company has a 50 day moving average price of $417.26 and a 200-day moving average price of $371.70. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $450.98.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same period in the prior year, the business posted $6.02 EPS. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts predict that Amgen Inc. will post 22.96 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s dividend payout ratio is presently 62.65%.

Insider Transactions at Amgen

In other news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 over the last 90 days. Company insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of analyst reports. Robert W. Baird boosted their price objective on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. TD Cowen raised their target price on shares of Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Oppenheimer restated an “outperform” rating on shares of Amgen in a report on Friday. Canaccord Genuity Group lifted their price target on shares of Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Finally, BMO Capital Markets cut their price target on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating on the stock in a report on Monday, October 12th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $389.71.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Strong lung-cancer data: Amgen’s Imdelltra, combined with AstraZeneca’s Imfinzi, reduced the risk of death by 58% in a Phase 3 trial of patients with small-cell lung cancer. Median overall survival reached 21.1 months, improving the commercial outlook for Imdelltra and supporting the shares. Amgen and AstraZeneca lung-cancer trial results
• Positive Sentiment: Constructive analyst action: Jefferies raised its Amgen price target to $428 from $410, while Oppenheimer reaffirmed its Outperform rating. The target increase reflects greater confidence following the clinical update. Jefferies raises Amgen price target Oppenheimer reiterates Amgen Outperform rating
• Neutral Sentiment: Board appointment: Amgen appointed David W. Gibbs to its board of directors. The move adds an experienced corporate leader but is unlikely to materially change near-term earnings expectations. Amgen appoints David W. Gibbs to board
• Neutral Sentiment: Barclays raised its target to $400 from $380, but the revised target remains below the recent trading level. Reported short interest of zero shares provides no meaningful bearish positioning signal. Barclays raises Amgen price target
• Negative Sentiment: Commercial uncertainty remains: Bank of America maintained a Sell rating and a $328 price target, arguing that encouraging Imdelltra data has not eliminated concerns about adoption, competition and the drug’s eventual commercial impact. Bank of America maintains Sell rating on Amgen

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.